Richard T. Kenney net worth and biography

Richard Kenney Biography and Net Worth

Dr. Kenney has more than 20 years of experience in translational-stage development of biologics, as well as the commercialization strategy and corporate management of preclinical, clinical-stage and commercialized vaccines and immunotherapies. As President of ClinReg Biologics, he has provided strategic consulting in clinical and regulatory affairs of biologics, medical monitoring and pharmacovigilance in several capacities. Dr. Kenney most recently served as Chief Development Officer at X-VAX Technology and previously held Chief Medical Officer roles at Immune Design and Crucell Holland, where he led the clinical development and regulatory affairs groups. Dr. Kenney was a researcher/reviewer for the FDA for over six years and did post-graduate training at Duke and NIH. Dr. Kenney received a B.S. in Chemistry from George Washington University and his M.D. from Harvard Medical School.

How old is Richard T. Kenney?: Dr. Kenney is currently 66 years old. There are 5 older executives and no younger executives at Sonnet BioTherapeutics. The oldest executive at Sonnet BioTherapeutics is Mr. Donald J. Griffith CPA, CPA, Controller & Director, who is 75 years old. Learn More on Richard T. Kenney's age.
How do I contact Richard T. Kenney?: The corporate mailing address for Dr. Kenney and other Sonnet BioTherapeutics executives is 100 OVERLOOK CENTER SUITE 102, PRINCETON NJ, 08540. Sonnet BioTherapeutics can also be reached via phone at 609-375-2227 and via email at [email protected]. Learn More on Richard T. Kenney's contact information.
Has Richard T. Kenney been buying or selling shares of Sonnet BioTherapeutics?: Richard T. Kenney has not been actively trading shares of Sonnet BioTherapeutics during the past quarter. Learn More on Richard T. Kenney's trading history.
Who are Sonnet BioTherapeutics' active insiders?: Sonnet BioTherapeutics' insider roster includes Richard Kenney (Insider), and Pankaj Mohan (CEO). Learn More on Sonnet BioTherapeutics' active insiders.
Are insiders buying or selling shares of Sonnet BioTherapeutics?: In the last year, Sonnet BioTherapeutics insiders bought shares 4 times. They purchased a total of 19,537 shares worth more than $105,416.74. The most recent insider tranaction occured on June, 14th when insider Susan Dexter bought 454 shares worth more than $6,991.60. Insiders at Sonnet BioTherapeutics own 2.0% of the company. Learn More about insider trades at Sonnet BioTherapeutics.
Information on this page was last updated on 6/14/2023.

Richard T. Kenney Insider Trading History at Sonnet BioTherapeutics

Richard T. Kenney Buying and Selling Activity at Sonnet BioTherapeutics

Sonnet BioTherapeutics Company Overview

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

Today's Range

Now: $1.77

$1.77

$1.79

50 Day Range

MA: $1.87

$1.51

$2.26

2 Week Range

Now: $1.77

$1.08

$26.40

Volume

1,065 shs

Average Volume

91,359 shs

Market Capitalization

$5.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story